Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(10;16)(q22;p13) KAT6B/CREBBP

Written2006-05José Luis Vizmanos
Departamento de Genética, Facultad de Ciencias, Universidad de Navarra, 31008 Pamplona, Navarra, Espana

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
ICD-Morpho 9989/3 Myelodysplastic syndrome, unclassifiable
Atlas_Id 1332
 
  G-band analysis. Partial karyotype showing the t(10;16)(q22;p13). Arrows indicate breakpoints in both chromosomes.

Clinics and Pathology

Disease Acute myeloid leukaemia (AML) M4/M5a and therapy-related myelodysplastic syndromes (MDS).
Epidemiology Very rare, only four cases described.
Clinics There is no erythrophagocytosis associated.
Treatment Bad response to chemotherapy.
Prognosis Poor.

Cytogenetics

 
  Fig2. FISH analysis. FISH using BACs RPCI-11 461A8 (green) and RPCI-11 95J11 (red) showing that the signal of 95J11, which covers the initial part of the CREBBP gene, is split between der(10) and der(16).
Additional anomalies First described in a 4-year-old girl with AML M5a with 47,XX,der(7)t(7;10)(p13;p11),+8,der(10)t(7;10)(p13;p11)t(10;16)(q22;p13),der(16)t(10;16)(q22;p13)/46,XX. Later it was also described in an 84-year-old male without erythrophagocytosis and with this sole cytogenetic aberration. In addition, a variant breakpoint was described in a 52-year-old japanese woman with a therapy-related myelodysplastic syndrome (t-MDS) and also this sole translocation. Finally, another fusion variant was described in an AML-M4 female patient with the t(10;16)(q22;p13) and a t(11;17)(q23;q21).
Variants There are no cytogenetic variants described, but there are molecular variants due to different breakpoints in the genes fused (see below).

Genes involved and Proteins

Gene Name KAT6B
Location 10q22.2
Note This gene is also involved in rearrangements observed in uterine leiomyomata.
Dna / Rna 18 exons spanning 206.0 Kb. Transcription is from centromere to telomere. Up to 7 alternative transcripts.
Protein Histone acetyltransferase MYST4 is located probably in the nucleous. And it is probably involved in both positive (N-terminus) and negative (C-terminus) regulation of transcription, maybe involved in cerebral cortex development, required for RUNX2-dependent transcriptional activation and ubiquitously expressed in adult human tissues.
Gene Name CREBBP
Location 16p13.3
Note This gene is also involved in t(8;16)(p11;p13) with MYST3. CREBBP fusion observed in M4 AML and therapy related AML; t(11;16)(q23;p13) with MLL CREBBP fusion observed also in therapy related. Mutations of CREBBP are associated with Rubinstein-Taybi syndrome.
Dna / Rna Up to 32 exons spanning 154,14 Kb. Transcription is from centromere to telomere and up to 3 alternative transcripts between 8,0 and 8,7 Kb.
Protein CREBBP is a wide expression histone acetyltransferase enzyme which locates in the nucleous. Function binds specifically to the DNA-binding protein CREB connecting it to the basal transcriptional machinery. Also acetylates non-histone proteins, like NCOA3 coactivator. It has an essential role in embryogenesis, cell differentiation, apoptosis, and proliferation and it is involved in the regulation of cell cycle during G1/S transition.

Result of the chromosomal anomaly

Hybrid gene
Description Fusion in-frame between MYST4 exon 17 and CREBBP exon 3. Variants fusing MYST4 exon 16 and CREBBP exon 5; MYST4 exon 17 and CREBBP exon 7 have also been described.
Transcript 5' MYST4-CREBBP 3'
Detection CREBBP-MYST4 has been also detected.
  
Fusion Protein
 
  Schematic representation of the fusion MYST4-CREBBP consequence of the t(10;16)(q22;p13). From up to down: MYST4 and CREBBP structures. H15 domain: domain in histone families 1 and 5; PHD zinc fingers: plant homeodomain (PHD) with a C4HC3-type motif, this domain is widely distributed in eukaryotes and it has been found in many chromatin regulatory factors; MOZ_SAS family region: this region has been suggested to be homologous to acetyltransferases but this similarity is not supported by sequence analysis; KIX domain: bind domain for CBP and P300, this domain also binds to transactivation domains of other nuclear factors including Myb and Jun.
Description In all cases published to date the breakpoints occur in the acidic domain of MYST4 but at different locations of the CREBBP protein: in the nuclear receptor-binding domain, in a C/H rich domain or between this domain and the KIX domain. The putative MYST4-CBP chimaeric protein retains the part of MYST4 that encodes the zinc fingers, two nuclear localization signals (NLS1 and NLS2), the HAT domain, and a portion of the acidic domain, and most of the CBP protein, including its HAT domain.
Oncogenesis MYST4 has a 60% identity and 66% similarity to MYST3. All the fusions involving this genes result in several fusion proteins that target the acidic domain of MYST3 and MYST4. The partner fusion partners share also functional regions. All the fusion proteins are suspected to be leukaemogenic as a consequence of aberrant histone acetylation and transcription regulation, due probably but not exclusively, to the concomitant presence of two HAT domains coming from the different partners.
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13).
Kojima K, Kaneda K, Yoshida C, Dansako H, Fujii N, Yano T, Shinagawa K, Yasukawa M, Fujita S, Tanimoto M
British journal of haematology. 2003 ; 120 (2) : 271-273.
PMID 12542485
 
Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia.
Murati A, Adélaïde J, Mozziconacci MJ, Popovici C, Carbuccia N, Letessier A, Birg F, Birnbaum D, Chaffanet M
British journal of haematology. 2004 ; 125 (5) : 601-604.
PMID 15147375
 
Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13).
Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billström R, Strömbeck B, Mitelman F, Johansson B
Human molecular genetics. 2001 ; 10 (4) : 395-404.
PMID 11157802
 
t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia.
Vizmanos JL, Larráyoz MJ, Lahortiga I, Floristán F, Alvarez C, Odero MD, Novo FJ, Calasanz MJ
Genes, chromosomes & cancer. 2003 ; 36 (4) : 402-405.
PMID 12619164
 

Citation

This paper should be referenced as such :
Vizmanos, JL
t(10;16)(q22;p13)
Atlas Genet Cytogenet Oncol Haematol. 2006;10(4):267-269.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/t1016q22p13ID1332.html


Other genes implicated (Data extracted from papers in the Atlas) [ 2 ]

Genes CREBBP KAT6B

Translocations implicated (Data extracted from papers in the Atlas)

 t(10;16)(q22;p13) KAT6B/CREBBP

External links

KAT6B (10q22.2) CREBBP (16p13.3)

KAT6B (10q22.2) CREBBP (16p13.3)

Mitelman databaset(10;16)(q22;p13) [Case List]    t(10;16)(q22;p13) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9989/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
Mitelman databaseKAT6B/CREBBP [MCList]  KAT6B (10q22.2) CREBBP (16p13.3)
TICdbKAT6B/CREBBP  KAT6B (10q22.2) CREBBP (16p13.3)
 
Disease databaset(10;16)(q22;p13) KAT6B/CREBBP
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jan 27 12:51:14 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.